Currently there are very few treatment options available for patients with gastric cancer. First and second line HER2 targeted therapies are approved for the roughly 20% of patients whose tumors are HER2+. Immune checkpoint inhibitors have not been wildly successful in gastric cancer, but pembrolizumab does have approval for patients with previously treated MSI-H tumors and in the third line for PD-L1+ tumors. Future development is focused on additional targeted therapies as well as immunotherapy combinations.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in gastric cancer to help guide strategic and tactical commercial development decisions for market participants.